Vapers Digest 26th March
Wednesday’s News at a glance:
Why the FDA is right about Zyn
Jonathan Foulds, MSNBC
The U.S. Food and Drug Administration recently authorized the marketing of 20 nicotine pouch products under the Zyn brand, including flavors like Wintergreen and the “unflavored” Chill. That authorization sparked a new round of proposed legislation, trend pieces and frustration. Meanwhile, the stock price for Philip Morris International Inc., which manufactures the smokeless product, has caught fire.
Pragmatism vs. Ideology: The Institute of Economic Affairs on the Future of Nicotine Pouches
Richard Crosby, The Daily Pouch
The Institute of Economic Affairs (IEA) published an interesting discussion paper recently that caught my eye. “Not Invented Here: Institutional Resistance to Practical Solutions” takes a look at how novel solutions often face ideological resistance. From weight loss drugs to nuclear energy, the paper looks at various examples of proven and pragmatic solutions that struggle against policymakers and pressure groups with entrenched political beliefs. Particularly interest to me of course was the reports section on smoking and the difficulties modern harm reduction products like nicotine pouches face.
Two From Clearing The Air
Vapes linked to lower cardiac risks in people with HIV, new study finds
Ali Anderson
Vapes may pose lower cardiovascular risks in people with HIV compared to cigarettes, a new study has found.
The UCLA-led study, published in the Journal of the American Heart Association, examined how smoking and vaping affect the early stages of atherogenesis – the build-up of fats and cholesterol in the arteries that can lead to a heart attack.
It found that vapes are less likely to cause changes associated with atherogenesis, compared to cigarettes, among people who had been diagnosed with HIV.

Visit Nicotine Science & Policy for more News from around the World